BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP) Files An 8-K Submission of Matters to a Vote of Security Holders

(a) The Annual Meeting of the Company was held on May 29, 2019.

(b) Shareholders voted on the matters set forth below.

Item 1. The shareholders elected each of the Company’s 11 nominees to serve as directors of the Company until the 2020 Annual Meeting based upon the following votes:

Item 2. The management proposal on the advisory vote to approve the compensation of our named executive officers was approved based upon the following votes:

Item 3. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for 2019 was ratified based upon the following votes:

Item 4. The shareholder proposal on shareholder right to act by written consent was not approved based upon the following votes:

About BRISTOL-MYERS SQUIBB COMPANY (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.